ID: ALA490775

Max Phase: Preclinical

Molecular Formula: C21H21N3O9S

Molecular Weight: 491.48

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@H](NC(=O)[C@H](C)NC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1)C(=O)O

Standard InChI:  InChI=1S/C21H21N3O9S/c1-13(19(25)23-14(2)21(27)28)22-20(26)16-5-9-18(10-6-16)34(31,32)33-17-7-3-15(4-8-17)11-12-24(29)30/h3-14H,1-2H3,(H,22,26)(H,23,25)(H,27,28)/b12-11+/t13-,14-/m0/s1

Standard InChI Key:  FUJQYXNKCSRFSS-GHYUOPHCSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 491.48

Molecular Weight (Monoisotopic): 491.0999

AlogP: 1.41

#Rotatable Bonds: 10

Polar Surface Area: 182.01

Molecular Species: ACID

HBA: 8

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 12

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.20

CX Basic pKa:

CX LogP: 1.94

CX LogD: -1.51

Aromatic Rings: 2

Heavy Atoms: 34

QED Weighted: 0.25

Np Likeness Score: -0.47

References

1. Chang CJ, Geahlen RL..  (1992)  Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.,  55  (11): [PMID:1479375] [10.1021/np50089a001]

Source

Source(1):

• Scientific Literature